Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-01-17 4:13 pm Purchase | 2024-12-31 | 13G | Immuneering Corporation IMRX | BENJAMIN J. ZESKIND | 3,978,168 12.800% | 291,026 (+7.89%) | Filing History |
| 2024-11-14 4:15 pm Sale | 2024-09-30 | 13G | Immuneering Corporation IMRX | Citadel Advisors LLC | 2,672 0.000% | -2,075,420 (-99.87%) | Filing History |
| 2024-11-14 3:03 pm Sale | 2024-09-30 | 13G | Immuneering Corporation IMRX | Cormorant Asset Management LP | 0 0.000% | -1,700,000 (Position Closed) | Filing History |
| 2024-04-15 6:10 pm Sale | 2024-04-03 | 13G | Immuneering Corporation IMRX | Cormorant Asset Management LP | 1,700,000 5.810% | -2,504,364 (-59.57%) | Filing History |
| 2024-04-10 12:58 pm Sale | 2024-03-31 | 13G | Immuneering Corporation IMRX | T. Rowe Price Associates, Inc. | 910,266 3.100% | -2,467,834 (-73.05%) | Filing History |
| 2024-04-05 12:21 pm Sale | 2024-03-31 | 13G | Immuneering Corporation IMRX | BlackRock Inc. BLK | 1,377,120 4.700% | -720,286 (-34.34%) | Filing History |
| 2024-03-27 1:12 pm Purchase | 2024-03-14 | 13G | Immuneering Corporation IMRX | Merrin Investors LLC | 2,770,386 9.460% | 365,000 (+15.17%) | Filing History |
| 2024-02-14 4:57 pm Sale | 2023-12-31 | 13G | Immuneering Corporation IMRX | Citadel Advisors LLC | 2,078,092 7.100% | -63,405 (-2.96%) | Filing History |
| 2024-02-14 10:03 am Sale | 2023-12-31 | 13G | Immuneering Corporation IMRX | T. Rowe Price Associates, Inc. | 3,378,100 11.500% | -241,460 (-6.67%) | Filing History |
| 2024-01-26 4:23 pm Purchase | 2023-12-31 | 13G | Immuneering Corporation IMRX | BlackRock Inc. BLK | 2,097,406 7.200% | 760,970 (+56.94%) | Filing History |
| 2024-01-16 4:37 pm Purchase | 2023-12-31 | 13G | Immuneering Corporation IMRX | BENJAMIN J. ZESKIND | 3,687,142 12.600% | 191,356 (+5.47%) | Filing History |
| 2023-05-05 11:52 am Sale | 2023-04-30 | 13G | Immuneering Corporation IMRX | BlackRock Inc. BLK | 1,336,436 4.600% | -11,948 (-0.89%) | Filing History |
| 2023-04-24 5:26 pm Purchase | 2023-04-20 | 13G | Immuneering Corporation IMRX | Cormorant Asset Management LP | 4,204,364 14.420% | 1,918,183 (+83.90%) | Filing History |
| 2023-02-14 3:13 pm Purchase | 2022-12-31 | 13G | Immuneering Corporation IMRX | Cormorant Asset Management LP | 2,286,181 8.660% | 33,553 (+1.49%) | Filing History |
| 2023-02-14 12:38 pm Purchase | 2022-12-31 | 13G | Immuneering Corporation IMRX | T. Rowe Price Associates, Inc. | 3,619,560 13.700% | 431,055 (+13.52%) | Filing History |
| 2023-02-14 08:14 am Purchase | 2022-12-31 | 13G | Immuneering Corporation IMRX | Citadel Advisors LLC | 2,141,497 8.100% | 83,349 (+4.05%) | Filing History |
| 2023-02-08 4:15 pm Purchase | 2022-12-31 | 13G | Immuneering Corporation IMRX | BENJAMIN J. ZESKIND | 3,495,786 13.100% | 138,507 (+4.13%) | Filing History |
| 2023-02-01 4:54 pm Sale | 2022-12-31 | 13G | Immuneering Corporation IMRX | BlackRock Inc. BLK | 1,348,384 5.100% | -367,786 (-21.43%) | Filing History |
| 2022-02-14 2:34 pm Purchase | 2021-12-31 | 13G | Immuneering Corporation IMRX | T. Rowe Price Associates, Inc. | 3,188,505 12.200% | 151,523 (+4.99%) | Filing History |
| 2022-02-14 06:22 am Sale | 2021-12-31 | 13G | Immuneering Corporation IMRX | Citadel Advisors LLC | 2,058,148 7.800% | -4,528 (-0.22%) | Filing History |